Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Class:IdLiteratureReference:9761580
_displayNameIDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
_timestamp2022-01-15 22:45:46
author[Person:9761579] Mondesir, Johanna
[Person:9761581] Willekens, Christophe
[Person:9761583] Touat, Mehdi
[Person:9761582] de Botton, Stéphane
created[InstanceEdit:9761584] Rothfels, Karen, 2022-01-15
journalJ Blood Med
pages171-80
pubMedIdentifier27621679
titleIDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
volume7
year2016
(literatureReference)[Reaction:9761822] NFE2L2 binds the IDH1 gene [Homo sapiens]
[BlackBoxEvent:9761844] NFE2L2-dependent IDH1 gene expression [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives (9761580)